Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Kwality Pharmaceuticals Ltd (KPL)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 539997 NSE: KPL Pharmaceuticals & Drugs | Small Cap | Kwality Pharma Share Price
₹3,709 -127.90 (-3.33%)
As on 22-Sep'26 11:37
Kwality Pharmaceuticals Ltd (KPL)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 539997 NSE: KPL Pharmaceuticals & Drugs | Small Cap | Kwality Pharma Share Price
₹3,709 -127.90 (-3.33%)
As on 22-Sep'26 11:37
Key Metrics
Valuation Multiples
Market Cap
₹3,981 Cr.
Current Price
₹3,709
52-Week Low / High
₹829 / 3,867
TTM EPS
₹78.1
TTM Sales
₹554 Cr.
Book Value per Share
₹343.5
P/E Ratio
49.12
Higher than its 5-year historical median
Industry PE
55.1
Price to Book (P/B)
11.17
Higher than its 5-year historical median
Price to Sales (P/S)
7.19
Higher than its 5-year historical median
EV/EBITDA
29.73
Higher than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
22.67%
Outperforms industry median
Return on Capital Employed (ROCE)
24.01%
Outperforms industry median
Return on Assets (ROA)
13.01%
Operating Profit Margin
23.5%
Net Profit Margin
13.39%
Gross Profit Margin
21.9%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
35.89%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
47.08%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
69.22%
Asset Quality
Promoter Holding
54.86%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹346 Cr.
Equity
₹10.4 Cr.
Face Value
₹10
All Time Low / High
₹20.43 / 3771.00
Check Before You Invest
Quality
Somewhat GoodValuation
OvervaluedCheck Valuation charts
Price Trend
Strong
Is Kwality Pharmaceuticals Ltd a good quality company?
Kwality Pharmaceuticals Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Kwality Pharmaceuticals Ltd performance compare with that of its Peers?
Revenue growth of Kwality Pharmaceuticals Ltd vs industry peers?
Kwality Pharmaceuticals Ltd revenue CAGR is 13.94%, compared to the industry median CAGR of 0%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of Kwality Pharmaceuticals Ltd?
Promoters hold 54.86% of the Kwality Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Kwality Pharmaceuticals Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 67.4% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Kwality Pharmaceuticals Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 19.5% | 19.4% | 21.5% | 18.5% | 26.5% | 97.2% | 12.3% | 13.6% | 18.3% | 23.9% | - |
| Value Creation Index ⓘ | 0.4 | 0.4 | 0.5 | 0.3 | 0.9 | 5.9 | -0.1 | 0.0 | 0.3 | 0.7 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 95.3 | 137 | 165 | 139 | 262 | 456 | 251 | 307 | 370 | 503 | 554 |
| Sales YoY Gr. | - | 43.6% | 20.7% | -16% | 88.6% | 74.4% | -45% | 22.4% | 20.5% | 35.9% | - |
| Adj EPS ⓘ | 3.7 | 4.5 | 7.3 | 8 | 14.6 | 114.6 | 29 | 27.9 | 38.4 | 65 | 78.1 |
| YoY Gr. | - | 19.9% | 63% | 9.4% | 83.9% | 683.7% | -74.7% | -3.8% | 37.4% | 69.4% | - |
| BVPS (₹) ⓘ | 24.6 | 29.2 | 36.5 | 44.6 | 59.5 | 175.2 | 193.9 | 217 | 255.4 | 320.5 | 345.2 |
| Adj Net Profit ⓘ | 3.9 | 4.6 | 7.5 | 8.3 | 15.2 | 119 | 30.1 | 29 | 39.8 | 67.5 | 81 |
| Cash Flow from Ops. ⓘ | 4 | -0.1 | 13 | 5.6 | 26.4 | 59.2 | 42.2 | 43.4 | 52.8 | 17 | - |
| Debt/CF from Ops. ⓘ | 4.7 | -275.3 | 2.2 | 6.2 | 1.6 | 0.9 | 2.1 | 2.3 | 2.1 | 7.7 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 20.3% | 14% | 26.1% | 35.9% | ||||
| Adj EPS ⓘ | 37.4% | 34.8% | 30.9% | 69.4% | ||||
| BVPSⓘ | 33% | 40.1% | 18.2% | 25.5% | ||||
| Share Price | 67.3% | 42.8% | 117.8% | 294.6% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 15.8 | 16.1 | 21.6 | 19.2 | 27.7 | 97 | 15.7 | 13.5 | 16.2 | 22.5 | 23.5 |
| Op. Profit Mgn % ⓘ | 9.6 | 8.4 | 9.2 | 10.2 | 11.2 | 37.7 | 24.3 | 21.7 | 21.7 | 23.5 | 24.4 |
| Net Profit Mgn % ⓘ | 4.1 | 3.4 | 4.6 | 6 | 5.8 | 26.1 | 12 | 9.4 | 10.8 | 13.4 | 14.6 |
| Debt to Equity ⓘ | 0.7 | 0.9 | 0.7 | 0.8 | 0.7 | 0.3 | 0.5 | 0.4 | 0.4 | 0.4 | - |
| Working Cap Days ⓘ | 157 | 155 | 154 | 203 | 126 | 129 | 319 | 276 | 265 | 254 | 123 |
| Cash Conv. Cycle ⓘ | 78 | 69 | 63 | 78 | 36 | 33 | 141 | 151 | 151 | 142 | 56 |
Valuation of Kwality Pharma - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 98 | 137 | 166 | 139 | 262 | 456 | 251 | 307 | 370 | 503 |
| Operating Expenses ⓘ + | 89 | 126 | 151 | 125 | 233 | 285 | 190 | 241 | 290 | 385 |
| Operating Profit ⓘ | 9 | 12 | 16 | 14 | 29 | 172 | 61 | 66 | 80 | 118 |
| Operating Profit Margin (%) | 9.0% | 8.5% | 9.4% | 10.2% | 11.0% | 37.6% | 24.2% | 21.6% | 21.7% | 23.5% |
| Other Income ⓘ + | 1 | 1 | 1 | 4 | 2 | 4 | 3 | 2 | 2 | 3 |
| Interest ⓘ | 2 | 2 | 2 | 3 | 3 | 3 | 7 | 10 | 10 | 11 |
| Depreciation ⓘ | 3 | 3 | 3 | 4 | 6 | 11 | 15 | 20 | 18 | 20 |
| Profit Before Tax ⓘ | 6 | 7 | 11 | 11 | 21 | 162 | 26 | 31 | 54 | 89 |
| Tax ⓘ | 2 | 3 | 3 | 3 | 6 | 42 | 6 | 7 | 14 | 22 |
| Profit After Tax | 3 | 4 | 8 | 8 | 15 | 120 | 19 | 24 | 40 | 67 |
| PAT Margin (%) | 3.3% | 3.2% | 4.5% | 5.9% | 5.7% | 26.3% | 7.7% | 7.7% | 10.8% | 13.4% |
| Adjusted EPS (₹) | 3.2 | 4.4 | 7.3 | 8.0 | 14.6 | 115.6 | 18.7 | 22.9 | 38.4 | 64.9 |
| Dividend Payout Ratio (%) | 9.30% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 26 | 30 | 37 | 46 | 61 | 181 | 201 | 224 | 264 | 332 | |
| Debt + | 18 | 26 | 26 | 31 | 35 | 43 | 78 | 86 | 98 | 115 | |
| Minority Interest | -0 | -1 | -1 | -1 | -1 | -1 | -1 | -2 | -2 | -2 | |
| Trade Payables | 13 | 22 | 17 | 23 | 26 | 35 | 35 | 44 | 56 | 102 | |
| Others Liabilities ⓘ | 15 | 19 | 26 | 33 | 45 | 83 | 41 | 42 | 29 | 43 | |
| Total Liabilities ⓘ | 71 | 96 | 105 | 132 | 166 | 341 | 354 | 394 | 446 | 590 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 16 | 16 | 23 | 43 | 57 | 92 | 120 | 139 | 146 | 156 | |
| CWIP ⓘ | 1 | 4 | 6 | 0 | 3 | 12 | 14 | 0 | 0 | 17 | |
| Investments ⓘ | 4 | 5 | 5 | 4 | 5 | 0 | 0 | 0 | 0 | 0 | |
| Inventories | 14 | 15 | 11 | 22 | 17 | 53 | 86 | 78 | 83 | 78 | |
| Trade Receivables | 23 | 37 | 38 | 30 | 36 | 69 | 72 | 114 | 154 | 280 | |
| Cash Equivalents | 3 | 2 | 1 | 2 | 6 | 13 | 7 | 6 | 15 | 4 | |
| Others Assets ⓘ | 11 | 17 | 20 | 32 | 43 | 101 | 53 | 56 | 47 | 55 | |
| Total Assets ⓘ | 71 | 96 | 105 | 132 | 166 | 341 | 354 | 394 | 446 | 590 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 4 | -1 | 14 | 6 | 27 | 61 | 41 | 43 | 53 | 17 |
| Cash Flow From Investing Activity ⓘ + | -7 | -6 | -12 | -18 | -23 | -63 | -48 | -26 | -29 | -35 |
| Cash Flow From Financing Activity ⓘ + | 5 | 5 | -2 | 12 | 1 | 6 | 1 | -17 | -14 | 7 |
| Net Cash Flow ⓘ | 2 | -1 | -0 | 0 | 4 | 3 | -6 | -1 | 10 | -11 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 14.41 | 16.51 | 23.13 | 20.1 | 28.21 | 99.66 | 10.15 | 11.16 | 16.36 | 22.67 |
| ROCE (%) | 19.56 | 19.17 | 21.89 | 18.46 | 26.35 | 97.93 | 12.27 | 13.57 | 18.36 | 24.01 |
| Asset Turnover Ratio | 1.61 | 1.65 | 1.65 | 1.17 | 1.75 | 1.8 | 0.72 | 0.82 | 0.88 | 0.97 |
| PAT to CFO Conversion(x) | 1.33 | -0.25 | 1.75 | 0.75 | 1.8 | 0.51 | 2.16 | 1.79 | 1.33 | 0.25 |
| Working Capital Days | ||||||||||
| Receivable Days | 75.40 | 79.20 | 82.80 | 90.10 | 46 | 41.90 | 102.40 | 110.60 | 132.50 | 157.60 |
| Inventory Days | 44.90 | 38.30 | 28.80 | 44.10 | 27.70 | 28.30 | 101.50 | 97.90 | 79.80 | 58.70 |
| Payable Days | 57.40 | 62.70 | 59.90 | 83.90 | 54.20 | 78.10 | 183.20 | 161.90 | 157.20 | 160.20 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Kwality Pharmaceuticals Ltd FAQs
The current trading price of Kwality Pharma on 22-Sep-2026 11:37 is ₹3,709.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 21-Sep-2026 the market cap of Kwality Pharma stood at ₹3,981.2 Cr
The latest P/E ratio of Kwality Pharma as of 21-Sep-2026 is 49.13.
The latest P/B ratio of Kwality Pharma as of 21-Sep-2026 is 11.11.
The 52-week high of Kwality Pharma is ₹3,866.6 and the 52-week low is ₹828.8.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Kwality Pharma is ₹554 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Kwality Pharmaceuticals Ltd is a average quality company.
The key valuation ratios of Kwality Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Kwality Pharmaceuticals Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About Kwality Pharmaceuticals Ltd
The company ‘Kwality Pharmaceuticals Limited’ was incorporated on May 04, 1983 vide Certificate of Incorporation issued by the Registrar of Companies, Punjab, H.P. and Chandigarh. It is engaged in the business of manufacturing of broad range of finished pharmaceutical formulations in a dosage form. It carries out its production through state-of-the-art manufacturing units situated at 6th Mile Stone, Village Nag Kalan, Majitha Road, Amritsar - 143006, Punjab, which is also its registered/administrative office and another manufacturing facility situated at 1-A Industrial Area, Raja ka bagh, Jassur, Himachal Pradesh. Both of its manufacturing facilities are well equipped and multiple products are manufactured at these facilities. Since incorporation, the company is ever progressing in Domestic and International market based on its commitment towards high quality and timely supplies. It provides specified and quality products for its customers while maintaining honesty, integrity and loyalty to its employees and customers.
The company has the most modern & sophisticated plant, equipments, technique and manpower. The company is ISO-9001:2000 and ISO 14001:2004 certified, and it is working with new SCHEDULE M and W.H.O. norms and certified with GMP and WHO certificate. The company’s production is based on standards laid down in pharmacopeia and technical reports series (TRS) guidelines of WHO (world health organization).
Milestones
- 1983: Incorporation of the company on May 04, 1983.
- 2007: Received ISO Certification.
- 2008: Commencement of new manufacturing unit at Jassur in Himachal Pradesh.
- 2009: Received status of Star Export House Certificate.
- 2012: Turnover increased by 75%.
- 2013: Incorporation of Subsidiary Company in Africa.
- 2014: Received WHO certification.
You have 48 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
